Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.45 |
| ▸ | PGR | P06401 | 9/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945854 | 0.86 | LOXL2 (0.46) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL3655671 | 0.85 | LOXL2 (0.40) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL27754238 | 0.78 | LOXL2 (0.44) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL3653908 | 0.78 | NR3C1 (0.55) | NR3C1PGRNR3C2LOXL2 | |
| SCHEMBL4431839 | 0.77 | CASR (0.43) | LOXL2CYP2D6MTNR1AMTNR1BCASR | |
| SCHEMBL28246983 | 0.77 | LOXL2 (0.55) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL5821510 | 0.75 | LOXL2 (0.43) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL5860946 | 0.74 | CYP2D6 (0.47) | NR3C1PGRNR3C2LOXL2CYP2D6 | |
| SCHEMBL31280332 | 0.74 | LOXL2 (0.55) | NR3C1PGRNR3C2LOXL2MTNR1A | |
| SCHEMBL9734545 | 0.73 | LOXL2 (0.58) | NR3C1PGRNR3C2LOXL2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522196-A | Treatment of infections and their sequelae with combined isolated glucocorticoid receptor agonists and anti-infective agents | BAUSCH & LOMB (US) | 2009-09-02 | — | — | CN | disclosed |
| CN-101522187-A | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | BAUSCH & LOMB (US) | 2009-09-02 | — | — | CN | disclosed |